Program
JBI-802
Its studies are mostly in Thrombocythemia, Essential · Neoplasm Metastasis, led by Jubilant Therapeutics.
Drug pageJBI-802: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jubilant Therapeutics | 22 open or running | phase 2since Feb 11, 2022 | Feb 11, 2022 | Jan 30, 2031phase 2 · NCT07612280 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2022First study: phase 2 study in Neoplasm MetastasisFirst studyNCT05268666 · 126 planned · United States
- Aug 11, 2025Phase 2 study in Thrombocythemia, EssentialNCT07612280 · 70 planned · Australia
Ahead
- Jan 30, 2031Primary completion: phase 2 study in Thrombocythemia, EssentialNCT07612280
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07612280Thrombocythemia, Essential · Australia | 2 | Recruiting | Jan 30, 2031 | 70 |
| NCT05268666Neoplasm Metastasis · United States | 2 | Recruiting | Dec 2024 | 126 |
How it is read
Names in the registry
- “JBI-802”, 2 entries
Conditions, from the studies’ own filings
- Thrombocythemia, Essential, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.